Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone for Early COVID-19
NCT04795583Phase 3Withdrawn
- Sponsor
- University of Alberta
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Prednisone with Placebo (2 arms). Primary endpoint: Hospital admission or death at 14 days. Planned start Aug 2021; status: withdrawn.
02
Drugs
prednisone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04795583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795583.